Point-of-Care Assessment of Platelet Reactivity After Clopidogrel to Predict Myonecrosis in Patients Undergoing Percutaneous Coronary Intervention

JACC: Cardiovascular Interventions

Volumn 3, Issue 3, 2010, Pages 318-323

  Mangiacapra, Fabio ^a,b   Barbato, Emanuele ^b   Patti, Giuseppe ^a   Gatto, Laura ^a   Vizzi, Vincenzo ^a   Ricottini, Elisabetta ^a   D'Ambrosio, Andrea ^a   Wijns, William ^b   Di Sciascio, Germano ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b OLV HOSPITAL   (Belgium)

Author keywords

high platelet reactivity; myocardial infarction; percutaneous coronary intervention; point of care platelet function test

Indexed keywords

CLOPIDOGREL; CREATINE KINASE; TROPONIN I;

AGED; ARTICLE; BIOASSAY; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUSCLE NECROSIS; PERCUTANEOUS CORONARY INTERVENTION; POINT OF CARE TESTING; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE AGGREGATION INHIBITION;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; BLOOD PLATELETS; CORONARY ARTERY DISEASE; CREATINE KINASE, MB FORM; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM; NECROSIS; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POINT-OF-CARE SYSTEMS; PREDICTIVE VALUE OF TESTS; RECEPTORS, PURINERGIC P2; RISK ASSESSMENT; RISK FACTORS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; TROPONIN I;

EID: 77949338825     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2009.12.012     Document Type: Article

References (25)

1. Patti G., Colonna G., Pasceri V., Pepe L.L., Montinaro A., and Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 111 (2005) 2099-2106
2. Gurbel P.A., Bliden K.P., Guyer K., et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study. J Am Coll Cardiol 46 (2005) 1820-1826
3. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
4. Angiolillo D.J., Bernardo E., Sabate M., et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 50 (2007) 1541-1547
5. Price M.J., Endemann S., Gollapudi R.R., et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29 (2008) 992-1000
6. Patti G., Nusca A., Mangiacapra F., Gatto L., D'Ambrosio A., and Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 52 (2008) 1128-1133
7. Marcucci R., Gori A.M., Paniccia R., et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 119 (2009) 237-242
8. Lev E.I., Patel R.T., Maresh K.J., et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47 (2006) 27-33
9. Buch A.N., Singh S., Roy P., et al. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. Am J Cardiol 99 (2007) 1518-1522
10. Cuisset T., Hamilos M., Sarma J., et al. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. Am J Cardiol 101 (2008) 1700-1703
11. Topol E.J., Ferguson J.J., Weisman H.F., et al., EPIC Investigator Group. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 278 (1997) 479-484
12. Tardiff B.E., Califf R.M., Tcheng J.E., et al., IMPACT-II Investigators. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. J Am Coll Cardiol 33 (1999) 88-96
13. Ioannidis J.P., Karvouni E., and Katritsis D.G. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol 42 (2003) 1406-1411
14. Herrmann J., Von Birgelen C., Haude M., et al. Prognostic implication of cardiac troponin T increase following stent implantation. Heart 87 (2002) 549-553
15. Prasad A., Singh M., Lerman A., Lennon R.J., Holmes D.R.J., and Rihal C.S. Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J Am Coll Cardiol 48 (2006) 1765-1770
16. Thygesen K., Alpert J.S., and White H.D. Universal definition of myocardial infarction. J Am Coll Cardiol 50 (2007) 2173-2195
17. Jeong Y.H., Kim I.S., Choi B.R., Kwak C.H., and Hwang J.Y. The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of-care VerifyNow P2Y12 assay. Eur Heart J (2008 Jul 9) [E-pub ahead of print]
18. Bhatt D.L., and Topol E.J. Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005?. Periprocedural cardiac enzyme elevation predicts adverse outcomes. Circulation 112 (2005) 906-915 discussion 923
19. Cutlip D.E., and Kuntz R.E. Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005?. Cardiac enzyme elevation after successful percutaneous coronary intervention is not an independent predictor of adverse outcomes. Circulation 112 (2005) 916-922 discussion 922
20. Selvanayagam J.B., Cheng A.S., Jerosch-Herold M., et al. Effect of distal embolization on myocardial perfusion reserve after percutaneous coronary intervention: a quantitative magnetic resonance perfusion study. Circulation 116 (2007) 1458-1464
21. Kong T.Q., Davidson C.J., Meyers S.N., Tauke J.T., Parker M.A., and Bonow R.O. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA 277 (1997) 461-466
22. Saw J., Densem C., Walsh S., et al. The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy. J Am Coll Cardiol Intv 1 (2008) 654-659
23. Cuisset T., Frere C., Quilici J., et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. J Am Coll Cardiol Intv 1 (2008) 649-653
24. Valgimigli M., Campo G., de Cesare N., et al., Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 119 (2009) 3215-3222
25. Morrow D.A., Wiviott S.D., White H.D., et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation 119 (2009) 2758-2764